News
Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.
A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...
Pharmalittle: We’re reading about Regeneron’s patent maneuvers, FDA rejection letters, and lots more
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...
Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and ...
Amgen is dealing with the threat of several fast-approaching patent expirations. The drugmaker's dividend streak is impressive, and the stock is trading at reasonable levels. Amgen (NASDAQ: AMGN) ...
The US subsidiary of South Korea-based Celltrion today announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) ...
Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...
Celltrion USA announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo), biosimilars referencing Prolia ...
StockStory.org on MSN14d
5 Insightful Analyst Questions From Amgen’s Q1 Earnings CallAmgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both general medicine and specialty disease areas. Management highlighted ...
Indian biosimilars developer Biocon Biologics, a subsidiary of Biocon Ltd has announced that the European Commission (EC) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results